[Federal Register: February 19, 2004 (Volume 69, Number 33)]
[Page 7760]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Vaccines and Related Biological Products Advisory Committee; 
Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Vaccines and Related Biological Products 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on March 17, 2004, from 1 
p.m. to 5 p.m.
    Location: Food and Drug Administration, 8800 Rockville Pike, Bldg. 
29B, Conference Room C, Bethesda, MD. This meeting will be held by a 
telephone conference call. The public is welcome to attend the meeting 
at the previously mentioned location. A speaker telephone will be 
provided at the specified location for public participation in this 
    Contact Person: William Freas or Denise H. Royster, Food and Drug 
Administration, Center for Biologics Evaluations and Research (HFM-71), 
1401 Rockville Pike, Rockville, MD, 20852, 301-827-0314, or FDA 
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in 
the Washington, DC area), code 3014512391. Please call the Information 
Line for up-to-date information on this meeting.
    Agenda: This committee will discuss recommendations pertaining to 
the influenza virus vaccine formulation.
    Procedure: On March 17, 2004, from 1 p.m. to 5 p.m., the meeting is 
open to the public. Interested persons may present data, information, 
or views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by March 11, 
2004. Oral presentations from the public will be scheduled between 
approximately 2 p.m. and 3 p.m. Time allotted for each presentation may 
be limited. Those desiring to make formal oral presentations should 
notify the contact person before March 11, 2004, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
    FDA welcomes the attendance of the public as its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact William Freas or 
Denise H. Royster at least 7 days in advance of the meeting.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: February 11, 2004.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 04-3487 Filed 2-18-04; 8:45 am]